Michael Chermak, CEO, $OZSC OZOP Surgical commented, "We are excited to have completed initial testing for this novel device. Only through testing can we learn how to create an optimal design and develop the instrumentation to allow for an exceptional operative outcome for the surgeon and patient. Developing an infinitely adjustable ALIF implant is a challenging design goal but the end outcome will allow the surgeon to ensure segmental stability and restore sagittal balance. We are encouraged by the results of this testing and have incorporated several improvements into our next design. We look forward to completing testing for FDA submission in the near future and hope to have our approval by the end of the year". https://finance.yahoo.com/news/ozop-surgical-...00883.html